← Leaderboards
Michael Bryer-Ash
University Of Tennessee Health Sci Ctr
$1,485,382
Attributed
$1,485,382
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $790K · FY2005–08$1M$750K$500K$250K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$1,485,382 · 3
By mechanism
R01$1,485,382 · 1
M01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Abbas E. Kitabchi$15,006,255
- James Martin Krueger$18,958,539
- M. Dennis Marcus Leo$1,900,000
- Chunxiang Zhang$4,904,212
- Pedro A Velasquez-Mieyer$572,831
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectAfrican AmericanPhenotypeEpidemiologyAcuteFamilyBody FatEating BehaviorAbdominal FatDrug Screening /EvaluationBlood Glucose RegulationCohortCombination ChemotherapyCutaneousBaseDepthDesignDiabetes Mellitus TherapyDiabetic AngiopathyCandidate Disease GeneDosageAdiponectinAbdomen
Grant awards (10)
Genetics of Adiposity and Glucose Homeostastis$79,453
R01 · FY2008 · HL · contact PI
Genetics of Adiposity and Glucose Homeostastis$5,000
R01 · FY2007 · HL · contact PI
Genetics of Adiposity and Glucose Homeostastis$537,049
R01 · FY2006 · HL · contact PI
Genetics of Adiposity and Glucose Homeostastis$252,932
R01 · FY2006 · HL · contact PI
Genetics of Adiposity and Glucose Homeostastis$517,393
R01 · FY2005 · HL
IRAS FAMILY STUDY: GENETICS OF INSULIN RESISTANCE$93,555
R01 · FY2003 · HL
Compare combined submaximal sulfonylurea and metformin therapy in NIDDM$0
M01 · FY2001 · RR
EPIDEMIOLOGY OF DIABETES AND COMPLICATIONS--EDIC$0
M01 · FY2001 · RR
EPIDEMIOLOGY OF DIABETES AND COMPLICATIONS--EDIC$0
M01 · FY2000 · RR
Compare combined submaximal sulfonylurea and metformin therapy in NIDDM$0
M01 · FY2000 · RR